175 related articles for article (PubMed ID: 24734908)
1. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.
Sidharta PN; Diamant Z; Dingemanse J
Fundam Clin Pharmacol; 2014 Dec; 28(6):690-9. PubMed ID: 24734908
[TBL] [Abstract][Full Text] [Related]
2. Setipiprant, a selective oral antagonist of human CRTH2: relative bioavailability of a capsule and a tablet formulation in healthy female and male subjects.
Baldoni D; Mackie A; Gutierrez M; Theodor R; Dingemanse J
Clin Ther; 2013 Nov; 35(11):1842-8. PubMed ID: 24095247
[TBL] [Abstract][Full Text] [Related]
3. A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.
Géhin M; Strasser DS; Zisowsky J; Farine H; Groenen PM; Dingemanse J; Sidharta PN
J Clin Pharmacol; 2015 Jul; 55(7):787-97. PubMed ID: 25655470
[TBL] [Abstract][Full Text] [Related]
4. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of setipiprant, a selective oral CRTH2 antagonist, in humans.
Hoch M; Wank J; Kluge I; Wagner-Redeker W; Dingemanse J
Drugs R D; 2013 Dec; 13(4):253-69. PubMed ID: 24214422
[TBL] [Abstract][Full Text] [Related]
6. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection.
Krause A; Zisowsky J; Strasser DS; Gehin M; Sidharta PN; Groenen PMA; Dingemanse J
Clin Pharmacokinet; 2016 Jul; 55(7):813-821. PubMed ID: 26692193
[TBL] [Abstract][Full Text] [Related]
8. Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist.
Fretz H; Valdenaire A; Pothier J; Hilpert K; Gnerre C; Peter O; Leroy X; Riederer MA
J Med Chem; 2013 Jun; 56(12):4899-911. PubMed ID: 23721423
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonist.
Géhin M; Lott D; Farine H; Issac M; Strasser D; Sidharta P; Dingemanse J
Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):711-721. PubMed ID: 30589994
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist.
Gehin M; Sidharta PN; Gnerre C; Treiber A; Halabi A; Dingemanse J
Eur J Clin Pharmacol; 2015 Jan; 71(1):15-23. PubMed ID: 25323804
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
Lai E; Wenning LA; Crumley TM; De Lepeleire I; Liu F; de Hoon JN; Van Hecken A; Depré M; Hilliard D; Greenberg H; O'Neill G; Metters K; Gottesdiener KG; Wagner JA
Clin Pharmacol Ther; 2008 Jun; 83(6):840-7. PubMed ID: 17882161
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
[TBL] [Abstract][Full Text] [Related]
14. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies.
Ratner P; Andrews CP; Hampel FC; Martin B; Mohar DE; Bourrelly D; Danaietash P; Mangialaio S; Dingemanse J; Hmissi A; van Bavel J
Allergy Asthma Clin Immunol; 2017; 13():18. PubMed ID: 28392807
[TBL] [Abstract][Full Text] [Related]
16. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma.
Kuna P; Bjermer L; Tornling G
Drug Des Devel Ther; 2016; 10():2759-70. PubMed ID: 27621597
[TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
19. Effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the steady-state pharmacokinetics of digoxin in healthy adult subjects.
Liu F; Vessey L; Wenning L; Connolly S; Buckland M; Johnson-Levonas AO; Denker A; Wagner JA; Lai E
J Clin Pharmacol; 2010 Jul; 50(7):823-8. PubMed ID: 20197486
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
